Obesity and heart failure-the role of GLP-1 receptor agonists.

IF 1.1 4区医学 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS

Herz Pub Date : 2025-04-02 DOI:10.1007/s00059-025-05312-2

Gregor Simonis, Ulrike Schatz

引用次数: 0

Abstract

Patients with obesity-driven heart failure with preserved ejection fraction (HFpEF) often suffer from symptoms despite guideline-recommended treatment with diuretics, sodium glucose cotransporter 2 (SGLT2) inhibition, and mineralocorticoid antagonists. Obesity by itself drives heart failure via multiple pathophysiological mechanisms. This review summarizes current data on glucagon-like peptide‑1 (GLP-1) receptor agonists and the dual GIP/GLP‑1 agonist tirzepatide, including symptoms and outcomes in patients with obesity-driven HFpEF with or without diabetes.

查看原文本刊更多论文

肥胖导致的射血分数保留型心力衰竭（HFpEF）患者尽管接受了指南推荐的利尿剂、钠葡萄糖共转运体 2（SGLT2）抑制剂和矿物质皮质激素拮抗剂治疗，但仍经常出现各种症状。肥胖本身通过多种病理生理机制导致心力衰竭。本综述总结了目前有关胰高血糖素样肽-1（GLP-1）受体激动剂和 GIP/GLP-1 双重激动剂替扎帕肽的数据，包括肥胖驱动的高频心力衰竭伴或不伴糖尿病患者的症状和预后。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Herz 医学-心血管系统

CiteScore

3.00

自引率

5.90%

发文量

审稿时长

4-8 weeks

期刊介绍： Herz is the high-level journal for further education for all physicians interested in cardiology. The individual issues of the journal each deal with specific topics and comprise review articles in English and German written by competent and esteemed authors. They provide up-to-date and comprehensive information concerning the speciality dealt with in the issue. Due to the fact that all relevant aspects of the pertinent topic of an issue are considered, an overview of the current status and progress in cardiology is presented. Reviews and original articles round off the spectrum of information provided.